Nemolizumab information

Nemolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	IL31RA
Clinical data
Other names	CIM-331
Routes of; administration	Subcutaneous injection
ATC code	D11AH12 (WHO) ;
Pharmacokinetic data
Metabolism	Proteolytic enzymes
Identifiers
CAS Number	1476039-58-3;
ChemSpider	none;
UNII	GN465U8B72;
KEGG	D11080;

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.^[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.^[2] Results of a Phase II clinical trial were published in March 2017.^[3]

Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.^[4]

^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3). World Health Organization: 411. 2015.
^ Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.

[1] Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).

[2] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3). World Health Organization: 411. 2015.

[3] Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.

[4] "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.